Evidence map›Paper›PMID 31772553›Full record

ArticleJournal of interventional cardiology2019

Nonemergent Percutaneous Coronary Intervention on an Unprotected Left Main Coronary Artery Supported with Impella® Heart Pump in Patients Ineligible for Surgical Revascularization.

Perwaiz M Meraj, Simon Dixon, Jeffery Moses, Karim Ibrahim, Andreas Schäfer, Ibrahim Akin, Jonathan Hill, Theodore Schreiber, William W O'Neill

Abstract read
In one paragraph

Article in Journal of interventional cardiology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Optimized patient selection in high-risk protected percutaneous coronary intervention.European heart journal supplements : journal of the European Society of Cardiology · 2022
    Article
  3. Left Main Coronary Artery Disease in Diabetics: Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting?The International journal of angiology : official publication of the International College of Angiology, Inc · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Perwaiz M MerajNorthwell Health, Department of Cardiology, Manhasset, NY 11030, USA.ORCID 0000-0002-6350-4666
Simon DixonBeaumont Health, Department of Cardiovascular Medicine, Royal Oak, MI 48073, USA.
Jeffery MosesColumbia University Medical Center, New York, NY 10032, USA.
Karim IbrahimTechnische Universität Dresden, Department of Internal Medicine and Cardiology, Dresden, Germany.
Andreas SchäferHannover Medical Center, Department of Cardiology and Angiology, Hannover, Germany.
Ibrahim AkinMannheim Medical School, Department of Cardiology and Angiology, Mannheim, Germany.
Jonathan HillKing's College Hospital, London SE5 9RS, UK.
Theodore SchreiberDetroit Medical Center, Department of Cardiology, Detroit, MI 48201, USA.
William W O'NeillHenry Ford Medical Center, Department of Interventional Cardiology and Structural Heart, Detroit, MI, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesWe sought to assess if ineligibility to coronary artery bypass grafting (CABG) constitutes a risk factor in patients who underwent a nonemergent unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with prophylactic Impella® heart pump support.

backgroundULMCA PCI in patients not deemed eligible for CABG is associated with significantly worse outcomes compared to ULMCA PCI in eligible patients.

methodsPatients from the cVAD Registry and the PROTECT II trial who underwent a nonemergent ULMCA PCI were identified. We compared in-hospital mortality and major adverse cardiac and cerebrovascular event (MACCE) rates as well as 30-day survival and MACCE rates between CABG ineligible and CABG eligible patients.

resultsA total of 331 patients were included (293 Impella 2.5®, 38 Impella CP®); 227 were ineligible for CABG and 104 were eligible. Baseline characteristics were remarkable for a trend toward higher rate of chronic obstructive pulmonary disease in the ineligible patients. In-hospital mortality (3.52% vs. 5.77%; p=0.383) and MACCE (6.61% vs. 7.69%; p=0.816) rates as well as 30-day survival (92.0% vs. 93.4%; Log-Rank p-value =0.781) and MACCE (88.1% vs. 90.1%; Log-Rank p-value=0.648) rates were not different between the two groups.

conclusionsThe results of our study suggest that prophylactic Impella support appears to mitigate the risks inherent to surgical ineligibility in patients undergoing a nonemergent ULMCA PCI. Our results require further investigation.

Indexed as

Coronary Artery BypassHeart-Assist DevicesPercutaneous Coronary InterventionAgedContraindications, ProcedureCoronary Artery DiseaseCoronary VesselsEligibility DeterminationFemaleHospital MortalityHumansMaleMiddle AgedOutcome Assessment, Health CareRegistriesRisk Factors

Identifiers

PMID31772553
PMCPMC6739763

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.